Bizueto-Rosas H, Salazar-Reyes A, Morán-Reyes EG, Soto-Hernández G, Muñoz-Martínez T

Language: Spanish
References: 15
Page: 30-34
PDF size: 861.37 Kb.

ABSTRACT

Castleman’s disease is a rare, lymphoproliferative disorder of unknown origin; it was first described in 1954 and defined in 1956 by Castleman. There are two clinicals types: monocentric or localized that usually demonstrates a localized and benign clinical course and multicentric that is characterized by generalized lymphadenopathy, systemic symptomatology and organomegaly. Its is the most aggressive and has the worst prognosis. Idiopathic. It is associated with chronic inflammation, immune deficiency, autoimmunity, and increased levels of interleucina-6. Recently the multicentric variety has been related to herpes virus associated to Kaposi sarcoma. The optimal therapeutic approach for the multicentric variety is unknown. Surgery has given excellent results for the monocentric variety. For non-resectable but islocated, radiotherapy with or without steroids induces its regression. Multicentric variety requires systemic therapy and generally has a poor outcome. A case is reported of a young female patient with a cervical mass, referred to us by the hemodynamic service, with a diagnosis of carotid paraganglioma in wich the surgical resection was both diagnostic and therapeutic until now.

REFERENCES

1. Sobrerilla-Calvo PJ, Avilés-Salas A, Cortés-Padilla DE, Rivas-Vera S. Características clinicopatológicas de la enfermedad de Castleman. Experiencia en el Instituto Nacional de Cancerología. Cir Ciruj 2009; 77: 187-92.

2. Frizzera G. Atypical lymphoproliferative disorders: when of age? Virchows Arch A Pathol Anat Histopathol 1993; 422: 261-3.

3. Flendrig JA. Benign giant lymphoma: clinicopathologic correlation study. In: Clark RI, Cumley RS, et al. The Year Book of Cancer. Chicago: Year Book Medical Publishers; 1970, p. 296-9.

4. Patel U, Forte V, Taylor G, Sirkin W. Castleman’s disease as a rare cause of a neck mass in a child. J Otolaryngol 1998; 27(3): 171-3.

5. Tuerlinckx D, et al. Unifocal cervical Castleman’s disease in two children. Eur J Pediatric 1997; 156: 701-3.

6. Ushio T, Yoshimura K, Kojima A, Tai H, Hanzawa T, Itsubo K, et al. A case of Castleman’s disease that recurred nine years after initial surgical removal. Nihon Kyobu Shikkan Gakkai Zasshi 1994; 32: 1175-8.

7. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 120: 657-62.

8. Leger-Ravet M, Peuchmaur M, Devergne O, et al. Interleukin 6 gene expression in Castleman disease. Blood 1991; 78: 2923-30.

9. Bartola F, Massarelli G, Soggia G, Tanda F. Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 1980; 73: 423-6.

10. Coca-Prieto M, Ortega-Jiménez V, Fernández-Ruiz J, Gavilán C, Carrasco F, Bermúdez R. Enfermedad de Castleman localizada: descripción de un caso y revisión de la literatura. An Med Interna (Madrid) 2003; 20(10): 534-6.

11. Viveros-Añorbe LM, Sánchez-Marle JF. Enfermedad de Castleman. Reporte de un caso en adolescente. An Med Asoc Med Hosp ABC 2001; 46(4): 193-6.

12. Remick SC, Patnaik M, Ziran NM, Liegmann KR, Dong J, et al. Human Herpes virus-8-associated disseminated angiosarcoma in an HIV-seronegative woman: Report of a case and limite case-control virologic study in vascular tumors. Am J Med 2000; 108: 660-4.

13. Frizera G, Peterson BA, Bayrd ED, Goldam A. A sistematic lymphoproliferative disorder with morphologic features of Castleman disease; Clinical findings and clinicopathologic correlation in 15 patients. J Clin Oncol 1985; 3: 1202-16.

14. Bowne WB, Lewis JJ, Filippa DA, Nieswizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman’s disease. Cancer 1999; 85: 706-17.

15. Shahidi H, Myers JL, Kvale PA. Castleman’s disease. Mayo Clin Proc 1995; 70: 969-77.